Vanda Pharmaceuticals Inc. SEC filings VNDA
Vanda Pharmaceuticals Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 10, 2009. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 5, 2026 | — |
| CORRESP | Letter to the SEC | Apr 24, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2026 | — |
| 8-A12B/A | Filing | Aug 8, 2024 | — |
| 8-A12B/A | Filing | May 3, 2024 | — |
| ARS/A | Amendment to annual report | Apr 29, 2024 | Dec 31, 2023 |
| 8-A12B | Filing | Apr 17, 2024 | — |
| EFFECT | Filing | May 5, 2023 | — |
| CORRESP | Letter to the SEC | May 3, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 16, 2023 | — |
| CT ORDER | Filing | Apr 24, 2020 | — |
| CT ORDER | Filing | Jun 26, 2017 | — |
| CT ORDER | Filing | May 4, 2017 | — |
| CT ORDER | Filing | Oct 4, 2016 | — |
| EFFECT | Filing | Jul 21, 2015 | — |
| CORRESP | Letter to the SEC | Jul 17, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2015 | — |
| CT ORDER | Filing | Jun 12, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2015 | — |
| CORRESP | Letter to the SEC | Feb 27, 2015 | — |
| CORRESP | Letter to the SEC | Jan 30, 2015 | — |
| CORRESP | Letter to the SEC | Jan 8, 2015 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2014 | — |
| CT ORDER | Filing | Jun 16, 2014 | — |
| EFFECT | Filing | Oct 4, 2013 | — |
| EFFECT | Filing | Feb 11, 2011 | — |
| CT ORDER | Filing | May 3, 2010 | — |
| 8-A12B/A | Form 8-a12b/a | Dec 22, 2009 | — |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VNDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- Accelerated filer
- SEC CIK
- 1347178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.